$120 Million - Initial Public OfferingJoint Bookrunner
Amicus Therapeutics, Inc.
$300 Million - Follow-OnCo-Bookrunning Manager
Avadel Pharmaceuticals plc
$144 Million - Exchangeable Senior NotesLead Bookrunning Manager
A / Site Visit Highlights Efforts to Drive Value to Customers and Gain Market Share / Outperform
AGN / Looking for Migraine Relief; A Closer Look at AGN’s Oral CGRPs
Healthcare / 2018 Outlook: Alpha Opportunities Abound in Healthcare Shares